Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ABUS
Arbutus Biopharma Corporation
Healthcare | Biotechnology
No licensed closing price on file for ABUS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
EPS (TTM)$0.79
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:14 UTC.
2025-08-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersRoger SawhneyEstimatedSEC 8-K →
2024-05-02Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersMichael SofiaEstimatedSEC 8-K →
2024-01-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
Arbutus Biopharma Corporation is a biotechnology company, listed on NASDAQ as ABUS.
When did ABUS last file with the SEC?
Arbutus Biopharma Corporation's most recent SEC filing on record is a 8-K filed 2026-05-27. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:14 UTC. This page is also available as JSON at /api/data?ticker=ABUS and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ABUS and 5,000+ tickers.
Oxford Ledge
Search